Format

Send to

Choose Destination
Am J Hematol. 2016 Jul;91(7):681-6. doi: 10.1002/ajh.24377. Epub 2016 May 11.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

Author information

1
CRIMM-Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, DENOTHE Excellence Center, University of Florence, Florence, Italy.
2
Center for Genome Research, and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
3
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
4
Department of Molecular Medicine, University of Pavia, Pavia, Italy.
5
Ospedale Di Circolo - Fondazione Macchi, University of Insubria, Varese, Italy.
6
Hematology and BMT Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
7
University of Siena, Siena, Italy.
8
Department of Clinical and Biological Sciences University of Turin, San Luigi Hospital Turin, Turin, Italy.
9
FROM Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
10
Department of Life Sciences, Centre for Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.

Abstract

Transformation to secondary myelofibrosis (MF) occurs as part of the natural history of polycythemia vera (PPV-MF) and essential thrombocythemia (PET-MF). Although primary (PMF) and secondary MF are considered similar diseases and managed similarly, there are few studies specifically focused on the latter. The aim of this study was to characterize the mutation landscape, and describe the main clinical correlates and prognostic implications of mutations, in a series of 359 patients with PPV-MF and PET-MF. Compared with PV and ET, the JAK2V617F and CALR mutated allele burden was significantly higher in PPV-MF and/or PET-MF, indicating a role for accumulation of mutated alleles in the process of transformation to MF. However, neither the allele burden nor the type of driver mutation influenced overall survival (OS), while absence of any driver mutation (triple negativity) was associated with significant reduction of OS in PET-MF, similar to PMF. Of the five interrogated subclonal mutations (ASXL1, EZH2, SRSF2, IDH1, and IDH2), that comprise a prognostically detrimental high molecular risk (HMR) category in PMF, only SRSF2 mutations were associated with reduced survival in PET-MF, and no additional mutation profile with prognostic relevance was highlighted. Overall, these data indicate that the molecular landscape of secondary forms of MF is different from PMF, suggesting that unknown mutational events might contribute to the progression from chronic phase disease to myelofibrosis. These findings also support more extended genotyping approaches aimed at identifying novel molecular abnormalities with prognostic relevance for patients with PPV-MF and PET-MF. Am. J. Hematol. 91:681-686, 2016.

PMID:
27037840
DOI:
10.1002/ajh.24377
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center